Loading...
•
Sep 30, 2022
NeoGenomics Q3 2022 Earnings Report
NeoGenomics' Q3 2022 results were announced, with a 6% increase in consolidated revenue to $129 million.
Key Takeaways
NeoGenomics reported a 6% increase in consolidated revenue, reaching $129 million for the third quarter of 2022. Clinical Services revenue increased by 4% to $106 million, while Pharma Services revenue saw an 18% increase to $23 million. The company's net loss for the quarter was $37 million, compared to a net loss of $20 million for the same period in 2021.
Consolidated revenue increased 6% to $129 million.
Clinical Services revenue increased 4% to $106 million.
Pharma Services revenue increased 18% to $23 million.
Consolidated gross profit for the third quarter of 2022 was $48.9 million, an increase of 4% compared to the third quarter of 2021.
Forward Guidance
This press release includes forward-looking statements regarding improving operational efficiency and returning to profitable growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...